Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all women will experience a UTI at some point in their lives, and about 30% will ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

Blujepa, the brand name for gepotidacin ... According to GSK, 16 million women in the U.S. struggle with UTIs each year, and ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug approved in decades and the first in a new class of medications. British ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic for uncomplicated urinary tract infections (uUTIs) in women and children aged 12 and older. Clinical trials showed its ...

Blujepa, the first new oral antibiotic for UTIs in 30 years, works by targeting bacterial DNA replication through dual ...

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all women will experience a UTI at some point in their lives, and about 30% ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...